In fact, several studies in animal models for obesity and NAFLD have recently demonstrated the beneficial effects of pharmacological stimulation of FXR and TGR5 on hepatic steatosis and insulin resistance. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.